ArticleScience progress
Low-dose urapidil mitigates renal ischemia-reperfusion injury through matrix metalloproteinase-9 inhibition and anti-inflammatory effects.
Article in Science progress. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ObjectiveEvaluate a low-urapidil protocol (30 µg/kg bolus + 20 µg/kg/h infusion) on oxidative stress, inflammation, apoptosis, and matrix metalloproteinase-9 (MMP-9)-mediated matrix remodeling in a rat renal ischemia-reperfusion (I/R) injury model.Methods32 male Wistar rats were randomized into control (CR), sham (SH), I/R, and I/R + Urapidil (UR) groups. The CR group received no treatment, the SH group underwent laparotomy and intraperitoneal normal saline, the I/R group underwent laparotomy with 30-min of aortic clamping and 24 h of reperfusion, and the UR group received urapidil starting at 1 h before 30-min of aortic clamping (ischemia), followed by 24 h of reperfusion. Assessments included serum creatinine/urea, oxidative markers (total antioxidant status [TAS, total oxidant status [TOS]), inflammatory cytokines (tissue necrosis factor-alpha [TNF-α], interleukin [IL]-1β, IL-6, and MMP-9) via enzyme-linked immunosorbent assay, renal histopathology (hematoxylin and eosin staining), and immunohistochemistry (H-scores for endothelial nitric oxide synthase [eNOS], caspase-3, TNF-α, IL-1β, IL-6, and MMP-9).ResultsI/R significantly increased serum creatinine, urea, TNF-α, IL-1β, and TOS, and depleted TAS, indicating severe injury, oxidative stress, and inflammation. Extensive tubular necrosis, vacuolization, and edema were also observed. Immunohistochemistry revealed elevated levels of eNOS, caspase-3, cytokines, and MMP-9. Urapidil pretreatment effectively normalized serum creatinine/urea, restored TAS, reduced TOS and cytokines (TNF-α, IL-1β, IL-6) to baseline, and markedly alleviated histopathological damage. Urapidil significantly suppressed I/R-induced elevations in oxidative (eNOS), apoptotic (caspase-3), and inflammatory markers, and MMP-9 expression.ConclusionLow-dose urapidil confers significant protection against renal I/R injury by mitigating oxidative stress, inflammation, apoptosis, and MMP-9-mediated matrix degradation. The efficacy at microgram doses highlights its potential as a clinically relevant nephroprotective agent.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.